Relmada Therapeutics (RLMD) Finished Goods (2012 - 2013)

Relmada Therapeutics (RLMD) reported Finished Goods of $4734.0 for Q4 2013, up 49.38% quarter-over-quarter from $3169.0 in Q3 2013.

Relmada Therapeutics (RLMD) Finished Goods (2012 - 2013) Analysis & Trends

Relmada Therapeutics (RLMD) has 2 years of Finished Goods data on file, last reported at $4734.0 in Q4 2013.

Finished Goods for Q4 2013 came in at $4734.0, changed N/A year-over-year; the trailing twelve-month figure through Nov 2013 was $4734.0 (changed N/A YoY), and the FY2013 annual result was $3169.0, down 50.52% from the prior year.
Finished Goods advanced to $4734.0 in Q4 2013 per RLMD's latest filing, from $3169.0 in the prior quarter.
Over five years, Finished Goods peaked at $6405.0 in Q3 2012 and troughed at $2369.0 in Q2 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Relmada Therapeutics	581.07 Mn	581.07 Mn	-

Download Data